HB 4124: Ivermectin; defining term; allowing ivermectin to be sold or purchased without prescription; immunity for pharmacy; effective date. - Oklahoma

House Committee Substitute → Floor (House) · 3 edits

MINOR

The bill was updated from the House Committee Substitute version to the Floor version, primarily changing the document header to reflect the House of Representatives. The core legislative text regarding the sale of ivermectin without a prescription, pharmacy liability protections, and the effective date of November 1, 2026, remains substantively unchanged. The changes are technical and formatting-related, intended to prepare the bill for final floor consideration.

Scope change

No change in the bill's scope or applicability; the policy content regarding ivermectin remains identical.

TECHNICAL

The document header was updated to identify the version as the 'House of Representatives - Floor Version' instead of just 'Committee Substitute'.

The list of sponsors was updated to include additional names (Townley, Adams, and Miller) alongside Fetgatter.

Page footers were updated to reflect the new 'Floor Version' designation and added a note indicating that bold face text denotes committee amendments.

Proposed Policy Committee Substitute 1 → House Committee Substitute · 3 edits

MINOR

The bill was amended to remove the 'Proposed Policy Committee' designation, indicating it has moved to a formal House Committee substitute stage. The committee number was updated from 16077 to 17042, and the effective date was changed from November 1, 2026, to November 1, 2027. The core policy allowing the sale of FDA-approved ivermectin without a prescription remains unchanged.

Scope change

The scope of the bill remains the same, focusing on allowing the over-the-counter sale of ivermectin, but the effective date has been pushed back by one year.

TIMELINE

The effective date for the new ivermectin sales law was changed from November 1, 2026, to November 1, 2027.

TECHNICAL

The internal committee reference number was updated from 16077 to 17042 to reflect the bill's progression through the legislative process.

The header text was updated to remove 'Proposed Policy' and simply state 'Committee Substitute', reflecting the bill's current status in the House.

Proposed Committee Substitute (full committee) 1 → Proposed Policy Committee Substitute 1 · 3 edits

MINOR

The bill was reclassified from a 'Proposed Oversight' substitute to a 'Proposed Policy' substitute, indicating a shift in legislative focus from monitoring to establishing new rules. The core policy change allows FDA-approved ivermectin for human use to be sold and purchased as an over-the-counter medication without a prescription or consultation with a healthcare professional. Additionally, the act's effective date was moved from November 1, 2026, to November 1, 2026, while the bill number and reference codes were updated to reflect the new policy status.

Scope change

The bill's scope expanded to explicitly authorize the sale and purchase of ivermectin without a prescription, changing it from a potentially monitored item to a freely accessible over-the-counter medication.

SCOPE

The bill title and header were changed from 'Proposed Oversight' to 'Proposed Policy', altering the legislative classification.

ELIGIBILITY

Added language allowing ivermectin suitable for human use to be sold or purchased without a prescription or consultation with a healthcare professional.

REQUIREMENT

Updated the bill number from 60-2-16980 to 60-2-16077 and changed the reference number from 16980 to 16077 to match the new policy classification.

Engrossed → Proposed Committee Substitute (full committee) 1 · 1 edit

MINOR

The bill text was completely replaced with a new version titled 'Proposed Oversight Committee Substitute.' This version retains the original intent to allow FDA-approved ivermectin for human use to be sold without a prescription but updates the document's metadata, including the bill title, committee name, and effective date information. The substantive policy language regarding the sale of ivermectin and pharmacy liability remains identical to the previous version.

Scope change

No change in the scope or applicability of the bill; the policy content regarding ivermectin remains the same.

TECHNICAL

The entire document text was replaced to reflect a new committee substitute version, changing the title and header information while keeping the core legislative text identical.

Introduced → Engrossed · 3 edits · Mar 25, 2026

MINOR

The bill was updated from an 'Introduced' draft to an 'Engrossed' version, reflecting changes made after review by the Senate. The most significant substantive change is the addition of a formal definition for 'over-the-counter medication' to clarify which ivermectin products are covered. The text was also reorganized to align with standard legislative formatting, including updated sponsor lists and page headers.

Scope change

The scope of the bill remains the same: allowing pharmacists to dispense FDA-approved ivermectin without a prescription. However, the definition of the medication is now explicitly included to prevent ambiguity.

DEFINITION

Added a new subsection defining 'over-the-counter medication' as FDA-approved ivermectin that can be legally sold without a prescription.

TECHNICAL

Reorganized the bill text to include a formal definition section (Subsection A) before the main provisions, replacing the previous direct start of the law.

Updated the sponsor list to include additional legislators (Townley, Adams, Murdock) and changed the header from 'Introduced' to 'Engrossed'.

Ivermectin; defining term; allowing ivermectin to be sold or purchased without prescription; immunity for pharmacy; effective date.

What changed between versions

How they voted

Actions timeline

Sponsors